• LAST PRICE
    0.5500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.5500
  • Day Range
    ---
  • 52 Week Range
    Low 0.5000
    High 6.4399
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.55
TimeVolumeERYP
09:32 ET1050.56
09:43 ET10000.5138
10:19 ET39390.5501
10:21 ET20990.5359
10:24 ET3000.5221
10:28 ET21000.5221
10:32 ET5000.540001
12:18 ET1000.5301
01:12 ET5800.5586
01:26 ET1000.55
01:32 ET44300.56
01:48 ET10000.6003
01:55 ET10000.6134
03:03 ET3000.6133
03:05 ET18500.6004
03:57 ET1000.5998
03:59 ET4930.5996
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesERYP
Erytech Pharma SA
18.5M
-0.5x
---
United StatesOPGN
OpGen Inc
19.0M
-0.4x
---
United StatesHGEN
Humanigen Inc
16.6M
-0.1x
---
United StatesJAGX
Jaguar Health Inc
19.1M
-0.2x
---
United StatesABEO
Abeona Therapeutics Inc
16.6M
-0.2x
---
United StatesAEZS
Aeterna Zentaris Inc
17.9M
-2.1x
---
As of 2022-10-04

Company Information

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.

Contact Information

Headquarters
60 avenue Rockefeller, Batiment AdenineLYON, France 69008
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Jean-Paul Kress
Chief Executive Officer, Director
Gil Beyen
Chief Financial Officer, Chief Operating Officer, Deputy General Manager
Eric Soyer
Chief Technical Officer
Stewart Craig
Deputy General Manager, Operations Chief Quality Officer and Qualified Person
Jerome Bailly

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$18.5M
Revenue (TTM)
$26.1M
Shares Outstanding
31.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.99
EPS
$-1.04
Book Value
$0.71
P/E Ratio
-0.5x
Price/Sales (TTM)
0.7
Price/Cash Flow (TTM)
---
Operating Margin
-100.89%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.